Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + 5-fluorouracil + vincristine + doxorubicin
- Development stage
- Unknown
- Lead developer
- Children's Oncology Group
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This is a four-drug chemotherapy combination regimen consisting of cisplatin, 5-fluorouracil (also known as fluorouracil or 5-FU), vincristine, and doxorubicin. Each component has a distinct mechanism of action targeting rapidly dividing cancer cells: - **Cisplatin** is a platinum-based compound that forms DNA crosslinks and induces apoptosis by interfering with DNA replication and transcription. - **5-Fluorouracil** is an antimetabolite that inhibits thymidylate synthase, blocking DNA synthesis. - **Vincristine** is a vinca alkaloid that disrupts microtubule formation during mitosis. - **Doxorubicin** is an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II. The combination has been studied primarily in pediatric oncology for the treatment of intermediate-risk unresectable hepatoblastoma (a type of liver cancer in children), where it demonstrated feasibility, tolerability, and efficacy. The addition of doxorubicin to the standard C5V regimen (cisplatin/fluorouracil/vincristine) was shown to intensify therapy for advanced disease[1][2][3]. This regimen may also be used or studied in other solid tumors.
- Other names
- C5VDC-5VDC 5VDC5V+Dcisplatin/5-fluorouracil/vincristine/doxorubicin
02
Targets
TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on cisplatin + 5-fluorouracil + vincristine + doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + 5-fluorouracil + vincristine + doxorubicin.